Markham, Canada

Arda Shahinian

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 15(Granted Patents)


Company Filing History:


Years Active: 2010-2012

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations in Immunology: The Contributions of Arda Shahinian

Introduction

Arda Shahinian, an accomplished inventor based in Markham, Canada, has made significant strides in the field of immunology. With a keen focus on T-cell activation, he has been awarded two patents that showcase his innovative approach to addressing T-cell mediated disorders.

Latest Patents

Arda's latest patents revolve around the development of polypeptides involved in immune response. These polypeptides comprise a receptor-ligand pair that plays a crucial role in T-cell activation. The patents also detail nucleic acid molecules encoding these polypeptides, along with vectors and host cells designed for expressing them. Such advancements have the potential to be utilized in treating various T-cell mediated disorders, highlighting the importance of his work in the medical field.

Career Highlights

Throughout his impressive career, Arda has worked with renowned companies including Amgen Inc. and Amgen Canada Inc. His experiences at these institutions have enriched his knowledge and expertise in biotechnology, facilitating the practical application of his innovative ideas in immunology.

Collaborations

Arda has had the opportunity to collaborate with notable professionals in the field, including Steven Kiyoshi Yoshinaga and Tak Wah Mak. These collaborations have undoubtedly contributed to the depth and effectiveness of his research, enabling him to make breakthroughs in immune response mechanisms.

Conclusion

Arda Shahinian stands out as a pioneering inventor whose work in the realm of immunology has led to significant advancements. His patents and collaborations exemplify the innovative spirit essential to addressing complex medical challenges. Arda's contributions are poised to make a lasting impact on the treatment of T-cell mediated disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…